Hologic Inc. recently published a transcript from their participation in the RBC Capital Markets 2025 Global Healthcare Conference, which took place on May 20, 2025. The event featured Karleen Oberton, Chief Financial Officer of Hologic, and was moderated by Conor McNamara, an analyst at RBC Capital Markets. During the conference, Oberton provided an overview of Hologic's focus on women's healthcare, highlighting their three primary divisions: Diagnostics, Breast Health, and their molecular diagnostics business anchored by the Panther high throughput instrument. She noted, "Hologic is a medical technology company uniquely focused in women's health care." Oberton also discussed the company's fiscal Q2 results, expressing satisfaction with their financial performance. "We delivered revenue and EPS at the high end of our guidance range for the quarter," she stated. However, she mentioned that there were some changes in guidance due to external factors, explaining that "China headwinds were offset by favorable FX," and mentioned a reduction in EPS range due to expected tariff impacts. The full transcript can be accessed through the link below.